NB-701
Undisclosed
DiscoveryActive
Key Facts
About Nerai Biosciences
Nerai Biosciences is a private, pre-clinical stage biotech founded in 2021 in Zurich, Switzerland. The company's core innovation is the MORPHEME platform, which integrates high-throughput directed evolution, functional screening, and machine learning to engineer novel CRISPR enzymes with superior specificity and activity. Nerai is advancing a proprietary pipeline of genome editing therapies for rare genetic diseases, with its lead program for Citrullinemia type 1 in in vivo lead optimization. The company is backed by non-dilutive grants and awards, positioning it to address previously inaccessible genetic mutations.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |
| Therapeutic Programs | Agathos Biologics | Pre-clinical |